An expert Q&A on the US Patent and Trademark Office’s (USPTO’s) 2025 guidance memoranda addressing the Patent Trial and Appeal Board’s (PTAB’s) approach to discretionary denials of inter partes review ...

Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

A Perfect Storm for Increased Patent Litigation in 2026 2026 is expected to be a record year for U.S. patent litigation, driven by pro-patent policies, advanced AI tools, and increased litigation ...

Adeia Inc. (Nasdaq: ADEA), a technology licensing firm, has initiated a major legal battle against Advanced Micro Devices, Inc. (AMD), alleging that the chip giant has infringed on ten of its ...

The landscape for discretionary denials at PTAB is evolving quickly; both patent challengers and owners must adapt their strategies to ensure they are not left behind by the USPTO’s new approach. The ...

“The Federal Circuit… ruled that such a due process violation could only be asserted by whoever claimed to be the true [patent owner].” Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) ...

Once the active ingredient is defined, an Applicant must select which patent, or patents, to put forward for extension. The statute permits only one PTE per regulatory review period, so the choice is ...